Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-814 in PiZZ Subjects with Alpha 1-Antitrypsin Deficiency
NCT04167345Phase 2Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of VX-814 in alpha-1 antitrypsin deficiency (AATD), sponsored by Vertex Pharmaceuticals. Started Jan 2020; status: terminated.
02
Drugs
VX-814
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT04167345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167345.